These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 37178794)
1. SARS-CoV-2 omicron BA.1.1 is highly resistant to antibody neutralization of convalescent serum from the origin strain. Li J; Li X; Mao H; Huang C; Sun Y; Miao L; Li J; Song W; Zhang Y; Huang J; Chen K Virus Res; 2023 Jul; 332():199131. PubMed ID: 37178794 [TBL] [Abstract][Full Text] [Related]
2. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants. Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520 [TBL] [Abstract][Full Text] [Related]
4. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections. Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K Front Immunol; 2022; 13():946318. PubMed ID: 35928813 [TBL] [Abstract][Full Text] [Related]
5. High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020. Zhang S; Ma P; Orzechowski M; Lemmer A; Rzasa K; Bagnall J; Barkho S; Chen M; He L; Neitupski R; Tran V; Ackerman R; Gath E; Bond A; Frongillo G; Cleland T; Golas A; Gaca A; Fitzgerald M; Kelly K; Hazegh K; Dumont L; Hoffman C; Homer M; Marks P; Woolley A; Wong S; Gomez J; Livny J; Hung D mBio; 2023 Apr; 14(2):e0352322. PubMed ID: 36786604 [TBL] [Abstract][Full Text] [Related]
6. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Zhang L; Li Q; Liang Z; Li T; Liu S; Cui Q; Nie J; Wu Q; Qu X; Huang W; Wang Y Emerg Microbes Infect; 2022 Dec; 11(1):1-5. PubMed ID: 34890524 [TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors. Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632 [TBL] [Abstract][Full Text] [Related]
8. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection. Kurhade C; Zou J; Xia H; Liu M; Yang Q; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Ren P; Xie X; Swanson KA; Shi PY Emerg Microbes Infect; 2022 Dec; 11(1):1828-1832. PubMed ID: 35792746 [TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 evolves to reduce but not abolish neutralizing action. Zhang Y; Ndzouboukou JB; Lin X; Hou H; Wang F; Yuan L; Gan M; Yao Z; Fu H; Cao J; Fan X J Med Virol; 2023 Jan; 95(1):e28207. PubMed ID: 36217880 [TBL] [Abstract][Full Text] [Related]
10. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Carreño JM; Alshammary H; Tcheou J; Singh G; Raskin AJ; Kawabata H; Sominsky LA; Clark JJ; Adelsberg DC; Bielak DA; Gonzalez-Reiche AS; Dambrauskas N; Vigdorovich V; ; Srivastava K; Sather DN; Sordillo EM; Bajic G; van Bakel H; Simon V; Krammer F Nature; 2022 Feb; 602(7898):682-688. PubMed ID: 35016197 [TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476 [TBL] [Abstract][Full Text] [Related]
12. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer. Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918 [TBL] [Abstract][Full Text] [Related]
13. Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants. Sun H; Xu J; Zhang G; Han J; Hao M; Chen Z; Fang T; Chi X; Yu C Viruses; 2022 Jun; 14(6):. PubMed ID: 35746803 [TBL] [Abstract][Full Text] [Related]
14. Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant. Ren W; Zhang Y; Rao J; Wang Z; Lan J; Liu K; Zhang X; Hu X; Yang C; Zhong G; Zhang R; Wang X; Shan C; Ding Q mBio; 2023 Apr; 14(2):e0041623. PubMed ID: 37010428 [TBL] [Abstract][Full Text] [Related]
15. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. Sullivan DJ; Franchini M; Joyner MJ; Casadevall A; Focosi D Nat Commun; 2022 Oct; 13(1):6478. PubMed ID: 36309490 [TBL] [Abstract][Full Text] [Related]
16. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model. Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747 [TBL] [Abstract][Full Text] [Related]
17. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. Syed AM; Ciling A; Taha TY; Chen IP; Khalid MM; Sreekumar B; Chen PY; Kumar GR; Suryawanshi R; Silva I; Milbes B; Kojima N; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Spraggon L; Tabata T; Ott M; Doudna JA Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2200592119. PubMed ID: 35858386 [TBL] [Abstract][Full Text] [Related]
18. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75. Wang Q; Iketani S; Li Z; Guo Y; Yeh AY; Liu M; Yu J; Sheng Z; Huang Y; Liu L; Ho DD Cell Host Microbe; 2022 Nov; 30(11):1512-1517.e4. PubMed ID: 36108630 [TBL] [Abstract][Full Text] [Related]
19. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion. Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815 [TBL] [Abstract][Full Text] [Related]
20. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]